TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22160847

Group type: EXPERIMENTAL
Intervention: Traditional triage method
Number of subjects: 40

Group type: COMPARATOR
Intervention: AHA-recommended method
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 40
Study: 20356583

Group type: EXPERIMENTAL
Intervention: 3D transvaginal sonography
Number of subjects: 39
Study: 18641116

Group type: EXPERIMENTAL
Intervention: Severe asthma
Number of subjects: 123
Study: 16180594

Group type: EXPERIMENTAL
Intervention: Continuous passive motion (CPM) treatment
Number of subjects: 35

Group type: COMPARATOR
Intervention: Therapist-supervised self-range of motion
Number of subjects: 35
Study: 14642083

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg bid plus amoxicillin 1000mg bid and levofloxacin 200mg bid
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Levofloxacin
Number of subjects: 85
Study: 10572788

Group type: EXPERIMENTAL
Intervention: Case management
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regular care
Number of subjects: 0
Study: 8545281

Group type: EXPERIMENTAL
Intervention: estramustine phosphate 600 mg/m2‐po daily for up to 2 years
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: cyclophosphamide 1 gram/m2‐IV every 3 weeks for 2 years
Number of subjects: 437

Group type: COMPARATOR
Intervention: observation only
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: estramustine phosphate
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: adjuvant therapy (any)
Number of subjects: 437

Group type: COMPARATOR
Intervention: extensive nodal disease (no adjuvant)
Number of subjects: 437
Study: 1678550

Group type: EXPERIMENTAL
Intervention: SKF-94482 400 mg at 0830 h
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: SKF-94482 400 mg at 1830 h
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo at 0830 h
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo at 1830 h
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: SKF-94482 200 mg or 300 mg at 0830 and 1830 h
Number of subjects: 45
Study: 29549394

Group type: COMPARATOR
Intervention: Transobturator inside-out mid-urethral sling (TOT)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Single-incision needleless mini-sling (SIMS)
Number of subjects: 201
Study: 27710241

Group type: EXPERIMENTAL
Intervention: Aromatase Inhibitors (AI)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Combination AI/GH
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 76
Study: 24423356

Group type: COMPARATOR
Intervention: Testosterone alone (n = 15)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Testosterone and growth hormone (n = 17)
Number of subjects: 32
Study: 22540970

Group type: EXPERIMENTAL
Intervention: Physiotherapy intervention consisting of several massage techniques, mobilizations, and local and global exercises.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Simple hand contact/touch to areas of pain (control group).
Number of subjects: 24
Study: 20047544

Group type: EXPERIMENTAL
Intervention: Single-dose azithromycin (30 mg/kg as a single dose)
Number of subjects: 306

Group type: COMPARATOR
Intervention: Amoxycillin (50 mg/kg/day in two divided doses for a minimum of 7 days)
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Single-dose azithromycin
Number of subjects: 306

Group type: COMPARATOR
Intervention: Amoxycillin
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 306
Study: 18282630

Group type: EXPERIMENTAL
Intervention: Impaired Glucose Tolerance (IGT)
Number of subjects: 4756

Group type: EXPERIMENTAL
Intervention: National Cholesterol Education Program (NCEP) definition of Metabolic Syndrome
Number of subjects: 4756

Group type: EXPERIMENTAL
Intervention: International Diabetes Federation (IDF) definition of Metabolic Syndrome
Number of subjects: 4756

Group type: EXPERIMENTAL
Intervention: WHO definition of Metabolic Syndrome
Number of subjects: 4756

Group type: EXPERIMENTAL
Intervention: All definitions of Metabolic Syndrome
Number of subjects: 4756
Study: 15647042

Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 24
Study: 12860945

Group type: EXPERIMENTAL
Intervention: Lanreotide (1 mg three times a day administered subcutaneously)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Interferon alfa (5 x 106 U three times a week subcutaneously)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Combination of lanreotide and interferon alfa
Number of subjects: 80
Study: 11310381

Group type: EXPERIMENTAL
Intervention: Intradermal HBV vaccine (20 mu gms) once a week for 6 weeks
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Intradermal HBV vaccine (20 mu gms) twice a week for 6 weeks
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Epo (phase 2) in addition to HBV
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Phase 2 patients (receiving Epo)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Phase 1 patients (not receiving Epo)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Epo and twice weekly vaccine (group 2 of phase 2)
Number of subjects: 85
Study: 8901851

Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg/day
Number of subjects: 1404
Study: 1725554

Group type: EXPERIMENTAL
Intervention: Propionibacterium granulosum KP‐45 (interferon inducer) + isoprinosine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TFX (thymus extract) + isoprinosine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Isoprinosine only
Number of subjects: 0
Study: 6643397

Group type: EXPERIMENTAL
Intervention: Alprazolam treatment
Number of subjects: 41

Group type: COMPARATOR
Intervention: Natural history control (no immediate treatment)
Number of subjects: 41
Study: 31282566

Group type: EXPERIMENTAL
Intervention: Low-normal targets for mean arterial pressure, arterial oxygen and carbon dioxide partial pressures
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: High-normal targets for mean arterial pressure, arterial oxygen and carbon dioxide partial pressures
Number of subjects: 120

Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 120
Study: 27154958

Group type: EXPERIMENTAL
Intervention: Undiagnosed Chlamydia trachomatis infection
Number of subjects: 2401

Group type: COMPARATOR
Intervention: No undiagnosed Chlamydia trachomatis infection
Number of subjects: 2401

Group type: EXPERIMENTAL
Intervention: Symptomatic Chlamydia trachomatis infection
Number of subjects: 2401

Group type: COMPARATOR
Intervention: No symptomatic Chlamydia trachomatis infection
Number of subjects: 2401
Study: 27458407

Group type: EXPERIMENTAL
Intervention: 4-session internet-based self-efficacy intervention
Number of subjects: 168

Group type: COMPARATOR
Intervention: Education control group
Number of subjects: 168
Study: 24983798

Group type: EXPERIMENTAL
Intervention: Cognitive restructuring
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Mindfulness
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control strategy
Number of subjects: 56
Study: 21949007

Group type: EXPERIMENTAL
Intervention: tocilizumab 8 mg/kg every 4 weeks
Number of subjects: 619

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 619
Study: 19700134

Group type: EXPERIMENTAL
Intervention: Heart Failure Patients
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Female HF Partners
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Male Partners
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: RAND-36 Mental Health Domain
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Depressive Symptoms
Number of subjects: 393
Study: 18269130

Group type: EXPERIMENTAL
Intervention: 250 ppm fluoride mouthrinse (100 ppm amine fluoride and 150 ppm sodium fluoride)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo mouthrinse
Number of subjects: 24
Study: 16286056

Group type: EXPERIMENTAL
Intervention: Inhaled zanamivir 10 mg once daily for 14 days
Number of subjects: 482

Group type: COMPARATOR
Intervention: Rimantadine 100 mg once daily for 14 days (for influenza A) or placebo (for influenza B)
Number of subjects: 482
Study: 12216096

Group type: EXPERIMENTAL
Intervention: Paclitaxel, carboplatin, and gemcitabine (Arm A)
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Paclitaxel, carboplatin, and vinorelbine (Arm B)
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Paclitaxel and gemcitabine (Arm C)
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Gemcitabine and vinorelbine (Arm D)
Number of subjects: 267

Group type: COMPARATOR
Intervention: Historic control (not specified)
Number of subjects: 267
Study: 10391957

Group type: EXPERIMENTAL
Intervention: IgG antibody levels against 38 kDa mycobacterial antigen (measured using ELISA based kits)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (healthy persons and patients with other conditions)
Number of subjects: 200
Study: 7543113

Group type: EXPERIMENTAL
Intervention: 600 mg testosterone buciclate (TB) injection
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 1200 mg testosterone buciclate (TB) injection
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both groups (600 mg and 1200 mg TB)
Number of subjects: 12
Study: 2702967

Group type: EXPERIMENTAL
Intervention: Pacing at 50 beats min‐1
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Pacing at 70 beats min‐1
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Pacing at 90 beats min‐1
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 6-min walk testing
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Weekly pedometer distance
Number of subjects: 18
Study: 946937

Group type: EXPERIMENTAL
Intervention: Low-lactose skim milk (15 g lactose, 2.5 cups)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Low-lactose skim milk (7.5 g lactose, 2.5 cups)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Regular skim milk (30 g lactose, 2.5 cups)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 25 g lactose in water (250 ml)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Skim milk (500 ml) with 25 g lactose
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Whole milk (500 ml) with 25 g lactose
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 10 g lactose in lactose-reduced skim (500 ml)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Whole milk (500 ml) with 10 g lactose
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo (250 ml)
Number of subjects: 33
Study: 31404466

Group type: EXPERIMENTAL
Intervention: 1-week nicotine replacement therapy sample (NRTS) including gum/patch and brief advice lasting 10 minutes
Number of subjects: 100

Group type: COMPARATOR
Intervention: Brief advice only (control)
Number of subjects: 100
Study: 31422079

Group type: EXPERIMENTAL
Intervention: Long-term proton pump inhibitors (PPIs) therapy (>12 months, n = 85)
Number of subjects: 203

Group type: COMPARATOR
Intervention: No proton pump inhibitors (non-PPI group, n = 118)
Number of subjects: 203
Study: 28358634

Group type: EXPERIMENTAL
Intervention: Alfaxalone 3 mg/kg IV
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Alfaxalone 5 mg/kg IV
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Alfaxalone 10 mg/kg IV
Number of subjects: 9
Study: 25010405

Group type: EXPERIMENTAL
Intervention: Steep Ramp Test (SRT)
Number of subjects: 40
Study: 23631544

Group type: EXPERIMENTAL
Intervention: Psychoanalytic therapy (mean duration: 39 months, mean dose: 234 sessions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Psychodynamic therapy (mean duration: 34 months, mean dose: 88 sessions)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psychoanalytic therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Psychodynamic therapy
Number of subjects: 0
Study: 20678841

Group type: EXPERIMENTAL
Intervention: Flapless extraction
Number of subjects: 27

Group type: COMPARATOR
Intervention: Flap extraction
Number of subjects: 27
Study: 18685141

Group type: EXPERIMENTAL
Intervention: PUFA (3 grams/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: RASB (control)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: PUFA
Number of subjects: 30
Study: 17101999

Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.5 mg)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 162

Group type: COMPARATOR
Intervention: PDT alone
Number of subjects: 162
Study: 15364796

Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg daily)
Number of subjects: 4491

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4491
Study: 11428270

Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Clindamycin + Gentamicin
Number of subjects: 60
Study: 9531327

Group type: EXPERIMENTAL
Intervention: Daunomycin-cytosine arabinoside with GM-CSF
Number of subjects: 318

Group type: COMPARATOR
Intervention: Daunomycin-cytosine arabinoside
Number of subjects: 318
Study: 8075874

Group type: EXPERIMENTAL
Intervention: maxEPA (eicosapentaenoic acid 0.178 g g‐1; docosahexaenoic acid 0.116 g g‐1) capsules 10 g per day for 28 days
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: maxEPA
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 2583158

Group type: EXPERIMENTAL
Intervention: Caffeinated drink at a dose of 5 mg.kg‐1 body mass and at the 3rd and 5th h of marching an additional drink at a dose of 2.5 mg.kg‐1 body mass
Number of subjects: 23

Group type: COMPARATOR
Intervention: Drink of equal volume
Number of subjects: 23
Study: 5478

Group type: EXPERIMENTAL
Intervention: Emotionally disturbed boys
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal boys
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Subjects with external locus of control
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: High anxious subjects
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Emotionally disturbed children classified as overanxious
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Anxiety and locus of control
Number of subjects: 40
Study: 31682542

Group type: EXPERIMENTAL
Intervention: Gefitinib plus carboplatin plus pemetrexed
Number of subjects: 345

Group type: COMPARATOR
Intervention: Gefitinib alone
Number of subjects: 345
Study: 30921221

Group type: EXPERIMENTAL
Intervention: homemade sheathless technique
Number of subjects: 1

Group type: COMPARATOR
Intervention: systemic nitroglycerin
Number of subjects: 1

Group type: COMPARATOR
Intervention: glonoin and verapamil
Number of subjects: 1
Study: 28282221

Group type: EXPERIMENTAL
Intervention: Microfracture with collagen augmentation (group 2)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Microfracture alone (group 1)
Number of subjects: 28
Study: 26485914

Group type: EXPERIMENTAL
Intervention: Wenyang Huazhuo Tongluo Recipe (WYHZTLR) plus methotrexate (MTX) and prednisone for 6 months
Number of subjects: 82

Group type: COMPARATOR
Intervention: Western medicine group (control) with methotrexate (MTX) and prednisone for 6 months
Number of subjects: 82
Study: 23713303

Group type: EXPERIMENTAL
Intervention: Sticking needling group
Number of subjects: 288

Group type: COMPARATOR
Intervention: Acupuncture group
Number of subjects: 288
Study: 21487312

Group type: EXPERIMENTAL
Intervention: Resistance exercise (RES) - 60 minutes, 2 sets of 8 repetitions at 80% 1RM
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (AER) - 60 minutes of cycling at 70% of VO2peak
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (CON) - resting condition
Number of subjects: 10
Study: 19228851

Group type: EXPERIMENTAL
Intervention: Fugl‐Meyer Assessment (FMA)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Action Research Arm Test (ARAT)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Wolf Motor Function Test (WMFT) functional ability scores
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Wolf Motor Function Test (WMFT) performance time score
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Wolf Motor Function Test (WMFT) performance time scores
Number of subjects: 57
Study: 16520168

Group type: EXPERIMENTAL
Intervention: Patients with perioperative myocardial ischemic injury (PMII)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Patients without perioperative myocardial ischemic injury (PMII)
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Patients with PMII
Number of subjects: 236

Group type: COMPARATOR
Intervention: Patients without PMII
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: High-risk open vascular operations
Number of subjects: 236
Study: 12627000

Group type: EXPERIMENTAL
Intervention: NIPSV with helium/oxygen (He/oxygen)
Number of subjects: 123

Group type: COMPARATOR
Intervention: NIPSV with air/oxygen
Number of subjects: 123
Study: 10381799

Group type: EXPERIMENTAL
Intervention: EMD 61753 (10 mg p.o.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EMD 61753 (0.1‐3.2 mg i.pl.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EMD 61753 (1.6 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9007598

Group type: EXPERIMENTAL
Intervention: Meropenem monotherapy (1 g intravenously every 8 hours)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Cefotaxime (2 g every 8 hours) plus metronidazole (0.5 g intravenously every 8 hours) for 5 to 10 days
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Meropenem monotherapy
Number of subjects: 94

Group type: COMPARATOR
Intervention: Cefotaxime/metronidazole combination
Number of subjects: 94
Study: 1645622

Group type: EXPERIMENTAL
Intervention: Etoposide 350 mg/m2
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Etoposide 370 mg/m2
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Etoposide (dose range 330-370 mg/m2)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Etoposide (dose > 300 mg/m2)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Etoposide
Number of subjects: 26
Study: 7016157

Group type: EXPERIMENTAL
Intervention: Oral misonidazole at a dose of 3 g/m2 preceding each of 4 weekly radiation doses
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control radiation group 1
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control radiation group 2
Number of subjects: 55
Study: 31547939

Group type: EXPERIMENTAL
Intervention: Intravenous sodium bicarbonate solution
Number of subjects: 916

Group type: COMPARATOR
Intervention: Intravenous saline solution
Number of subjects: 916

Group type: EXPERIMENTAL
Intervention: Oral N-acetylcysteine
Number of subjects: 916

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 916
Study: 30615068

Group type: EXPERIMENTAL
Intervention: Dietary pattern rich in calcium, potassium, and protein
Number of subjects: 401
Study: 28017489

Group type: EXPERIMENTAL
Intervention: Video telehealth intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Other intervention group
Number of subjects: 0
Study: 25709422

Group type: EXPERIMENTAL
Intervention: Management of prevalent delirium in general medical wards
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Management of prevalent delirium in geriatric medical wards
Number of subjects: 116
Study: 25161293

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Patients with functional movement disorders
Number of subjects: 14
Study: 22247354

Group type: EXPERIMENTAL
Intervention: Ocrelizumab (OCR) 50 mg
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Ocrelizumab (OCR) 200 mg
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Ocrelizumab (OCR) 500 mg
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Ocrelizumab (OCR) (combined groups)
Number of subjects: 152
Study: 20085455

Group type: EXPERIMENTAL
Intervention: FKD peptide and p(S/T)F antibody
Number of subjects: 1200000

Group type: EXPERIMENTAL
Intervention: Plk1 deletion mutant
Number of subjects: 1200000

Group type: EXPERIMENTAL
Intervention: Full-length active-mutant Plk1
Number of subjects: 1200000
Study: 16857266

Group type: EXPERIMENTAL
Intervention: Nefazadone alone (MED)
Number of subjects: 681

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral analysis system of psychotherapy alone (CBASP)
Number of subjects: 681

Group type: EXPERIMENTAL
Intervention: Both treatments (COMB)
Number of subjects: 681

Group type: COMPARATOR
Intervention: Medication side-effects
Number of subjects: 681

Group type: COMPARATOR
Intervention: Therapeutic alliance scores
Number of subjects: 681
Study: 16246781

Group type: EXPERIMENTAL
Intervention: aceclidine 0.016%
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: aceclidine 0.032%
Number of subjects: 30

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study: 12170039

Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine infusion
Number of subjects: 30

Group type: COMPARATOR
Intervention: 0.9% saline infusion
Number of subjects: 30
Study: 10502578

Group type: EXPERIMENTAL
Intervention: Laser slit lamp
Number of subjects: 62

Group type: COMPARATOR
Intervention: LOCS III
Number of subjects: 62
Study: 8786596

Group type: EXPERIMENTAL
Intervention: Topical anaesthetic at 42 degrees C (amethocaine 1%)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Topical anaesthetic at 42 degrees C (oxybuprocaine 0.4%)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Topical anaesthetic at 42 degrees C (lignocaine 4%)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Topical anaesthetic at room temperature (amethocaine 1%)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Topical anaesthetic at room temperature (oxybuprocaine 0.4%)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Topical anaesthetic at room temperature (lignocaine 4%)
Number of subjects: 60
Study: 3177196

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 42

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Combination therapy (Metoprolol + Nifedipine)
Number of subjects: 42
Study: 31680502

Group type: EXPERIMENTAL
Intervention: GlideScope®
Number of subjects: 120

Group type: COMPARATOR
Intervention: MDL
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 120